Tyra Biosciences, Inc. (TYRA) intrinsic value & 10-year financials
Tyra Biosciences, Inc. (TYRA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $18.52
- Market cap
- $1.1B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -202.5%
- Free cash flow (FY2025)
- -$95.3M
TYRA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$119.9M | -$2.01 | -$95.3M | — | -59.8% |
| FY2024 | — | -$86.5M | -$1.51 | -$70.4M | — | -50.9% |
| FY2023 | — | -$69.1M | -$1.62 | -$50.9M | — | -99.0% |
| FY2022 | — | -$55.3M | -$1.32 | -$50.8M | — | -1223.3% |
| FY2021 | — | -$26.3M | -$0.64 | -$24.4M | — | 185.6% |
| FY2020 | — | -$9.3M | — | -$8.1M | — | 32.2% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Tyra Biosciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Tyra Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -31.3% ROIC.
Tyra Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Tyra Biosciences, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.